United Guardian INC

United-Guardian announced a cash dividend of $0.30 per share, a 20% increase from the previous dividend, marking the 31st consecutive year of dividend payments.

United-Guardian, Inc. reported the results of its 2026 Annual Meeting of Stockholders, including the election of directors and advisory votes on executive compensation and auditor ratification.

United-Guardian, Inc. announced a significant increase in first-quarter 2026 sales and net income, driven by strong performance in its pharmaceutical and cosmetic ingredient segments.

United-Guardian, Inc. reported a 13% decrease in net sales and a significant drop in net income for fiscal year 2025, primarily due to reduced cosmetic ingredient sales.

United-Guardian's Board of Directors declared a $0.25 per share cash dividend, marking its 31st consecutive year of dividend payments.

United-Guardian, Inc. reported a significant decline in third-quarter and nine-month sales and net income for 2025, primarily due to reduced cosmetic ingredient purchases by its largest marketing partner, Ashland Specialty Ingredients.

United-Guardian reports a 16% increase in Q1 2026 net sales, driven by strong performance in pharmaceutical products and cosmetic ingredients, alongside a significant settlement income.

United-Guardian, Inc. reported a significant decline in net sales and net income for Q3 2025, primarily driven by a sharp drop in cosmetic ingredient sales to China.

United-Guardian, Inc. reported a significant decline in net sales and net income for the second quarter and first half of 2025, primarily driven by reduced demand for cosmetic ingredients in China due to tariffs and trade uncertainty.

United-Guardian's Q1 2025 net sales decreased by 24% year-over-year, primarily due to lower cosmetic ingredient sales, despite growth in pharmaceutical and medical lubricant segments.

United-Guardian Inc. saw a slight increase in net sales for the third quarter of 2024, with significant growth in cosmetic ingredient sales offsetting declines in pharmaceutical sales.

United-Guardian, Inc. saw a significant increase in net sales and profitability in the second quarter and first half of 2024, primarily driven by strong demand for its cosmetic ingredients.

United-Guardian, Inc. reported a 13% decrease in total sales for 2025, driven by a significant decline in cosmetic ingredient sales, while pharmaceutical and medical lubricant sales saw growth.

United-Guardian, Inc. reports a 12% increase in sales and improved profitability for the fiscal year ended December 31, 2024, driven by strong performance in cosmetic ingredients.

United-Guardian, Inc. released its annual 10-K report, outlining its financial results for 2023, strategic shifts, and future outlook, including a focus on new product development and market expansion.

United Guardian Inc. Director Kenneth H. Globus reported a gift of 7,480 shares of common stock, reducing his indirect beneficial ownership.

United-Guardian, Inc. has scheduled its 2026 virtual Annual Meeting of Stockholders for May 13, 2026, to address director elections, executive compensation, and auditor ratification.

United-Guardian, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on May 15, 2025, to elect directors, vote on executive compensation, and ratify the appointment of its independent accounting firm.

United-Guardian, Inc. will hold its annual meeting of stockholders virtually on May 15, 2024, to vote on the election of directors, executive compensation, and the ratification of its independent accounting firm.